← Leaderboards
Nigel Bourne
University Of Texas Medical Br Galveston
$10,520,495
Attributed
$10,520,495
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.5M · FY2005–14$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$10,520,495 · 8
By mechanism
UC7$7,005,691 · 1
R01$1,335,937 · 1
N01$864,934 · 1
R21$743,653 · 2
U54$406,202 · 2
R41$164,078 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Medical Br Galveston
Same institution · by research overlap
- Shinji Makino$11,956,927
- David H Walker$27,320,724
- David William Good$4,997,715
- Stanley J Watowich$2,525,942
- Clarence J. Peters$8,677,200
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseScreening ProcedureContainmentNovel TherapeuticsLifeHigh Throughput ScreeningPathogenVirus ReplicationDiagnosticResearch InfrastructureGenital HerpesProgramsResourcesAntiviral AgentsLaboratory MouseResearch PersonnelDisease /Disorder ModelInfectionCost EffectiveIn Vitro AssayBasic ScienceCommunitiesEnsureAssay Development
Grant awards (17)
Therapeutic immunization to impact HSV-2 latency and associated pathogenesis$232,500
R21 · FY2014 · AI · contact PI
Therapeutic immunization to impact HSV-2 latency and associated pathogenesis$181,538
R21 · FY2013 · AI · contact PI
Advance Technologies$2,142,856
UC7 · FY2010 · AI · contact PI
Advance Technologies$2,142,856
UC7 · FY2009 · AI · contact PI
Immunization to Reduce Genital and Neonatal Herpes$204,012
R01 · FY2009 · AI · contact PI
Identification and Characterization of Novel Flavivirus Antivirals$134,678
U54 · FY2009 · AI · contact PI
Advance Technologies$1,714,285
UC7 · FY2008 · AI · contact PI
Identification and Characterization of Novel Flavivirus Antivirals$271,524
U54 · FY2008 · AI · contact PI
Advance Technologies$938,044
UC7 · FY2007 · AI · contact PI
DRUG DEVELOPMENT FOR OPPORTUNISTIC INFECTIONS - CELL AND ANIMAL MODEL DEVELOPMEN$864,934
N01 · FY2007 · AI · contact PI
Immunization to Reduce Genital and Neonatal Herpes$327,372
R01 · FY2006 · AI · contact PI
Advance Technologies$67,650
UC7 · FY2006 · AI · contact PI
Immunization to Reduce Genital and Neonatal Herpes$335,250
R01 · FY2005 · AI
Immunization to Reduce Genital and Neonatal Herpes$335,250
R01 · FY2004 · AI
Morpholino Antisense Drugs for Hepatitis C Virus$164,078
R41 · FY2004 · DK
Immunization to Reduce Genital and Neonatal Herpes$134,053
R01 · FY2003 · AI
Immunization to Reduce Genital and Neonatal Herpes$329,615
R21 · FY2002 · AI